Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab)
- PMID: 17549402
Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab)
Abstract
Rituximab is the first anti-cancer antibody approved by the FDA for the treatment of B-cell non-Hodgkin lymphoma (B-NHL), alone or in combination with chemotherapeutic drugs. Further, rituximab is now being examined in a variety of CD20+ neoplastic diseases as well as B-cell-induced autoimmune diseases. The clinical response to rituximab is significant, resulting not only in tumor regression but also prolongation of survival. However, a subset of patients does not initially respond to rituximab or develops resistance to its further treatment. Therefore, alternative therapies for these patients are strongly desired. Rituximab activity has been thought to be by antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis, and studies in model systems established the role of rituximab in cell signaling-induced perturbation of anti-apoptotic survival pathways, suggesting that the patients unresponsive to rituximab may be overcome with other CD20 antibodies with different activities. This study investigated eight novel murine antibodies directed against CD20 for their physical and biological properties in comparison with 2B8 and c2B8 (rituximab). These antibodies were derived by various antigenic and immunization procedures and selected for CD20 activity. Analysis of these antibodies revealed that they all bound to various B-cell lines and CD20-transfected CHO cells. Six of the eight antibodies shared similar variable-region amino acid sequences that were also shared by 2B8 while two monoclonal antibodies did not. Of them, 1K1791 has a distinct heavy chain and both 1K1791 and 1K1782 have distinct light chains. Not all of the antibodies inhibited cell growth and only two antibodies reacted with fixed GST-CD20 recombinant fusion protein. Noteworthy, 1K1791 was found to inhibit cell proliferation and also induced caspase-independent apoptosis in the absence of cross-linker. These findings identified new antibodies with properties and epitope specificities different from 2B8. The potential clinical application of such antibodies in the treatment of B-NHL and rituximab-resistant B-NHL is discussed.
Similar articles
-
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.Oncogene. 2005 Mar 24;24(13):2121-43. doi: 10.1038/sj.onc.1208349. Oncogene. 2005. PMID: 15789036 Review.
-
Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.Cancer Lett. 2010 Aug 1;294(1):66-73. doi: 10.1016/j.canlet.2010.01.023. Epub 2010 Mar 3. Cancer Lett. 2010. PMID: 20202740
-
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.Haematologica. 2002 Jan;87(1):33-43. Haematologica. 2002. PMID: 11801463
-
Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.Cancer Res. 2008 Apr 1;68(7):2400-8. doi: 10.1158/0008-5472.CAN-07-6663. Cancer Res. 2008. PMID: 18381448
-
Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.Oncogene. 2007 May 28;26(25):3629-36. doi: 10.1038/sj.onc.1210365. Oncogene. 2007. PMID: 17530016 Review.
Cited by
-
Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigen.Iran Biomed J. 2012;16(3):121-6. doi: 10.6091/ibj.1082.2012. Iran Biomed J. 2012. PMID: 23023212 Free PMC article.
-
Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.Cancer Med. 2013 Apr;2(2):130-43. doi: 10.1002/cam4.60. Epub 2013 Feb 20. Cancer Med. 2013. PMID: 23634281 Free PMC article.
-
Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope.Cancer Sci. 2010 Jan;101(1):201-9. doi: 10.1111/j.1349-7006.2009.01392.x. Epub 2009 Oct 10. Cancer Sci. 2010. PMID: 19930155 Free PMC article.
-
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.J Biol Chem. 2016 Nov 11;291(46):23869-23881. doi: 10.1074/jbc.M116.733600. Epub 2016 Sep 20. J Biol Chem. 2016. PMID: 27650494 Free PMC article.
-
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4. MAbs. 2013. PMID: 23211638 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials